Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer -
- 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer -
- 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cance...
AlphaVax Announces Promising Results in Melanoma Studies
RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- AlphaVax announced today the presentation of promising
results from a collaboration with researchers at the Memorial Sloan-Kettering Cancer Center (MSKCC). Francesca Avogadri, Ph.D., a Research Fellow in the Department of Medicine at MSKCC prese...
Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure
Data Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session; Results Published On-Line in The Lancet
SAN MATEO¿ Calif.¿ March 29 /PRNewswire/ -- Corthera Inc. today announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter,...
Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
- Subcutaneous Administration of MSI-1436 in DIO Rats Highlighted -
PLYMOUTH MEETING, Pa., Jan. 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the tre...
Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
First Compound Sourced from China Shows Strong Results Presented at Cambridge Healthtech Institute Fall Conference
BOSTON, Oct. 23 /PRNewswire/ -- CHI -- Chipscreen Biosciences
(Chipscreen) and HUYA Bioscience International (HUYA) today described the
preclinical profile and outco...
Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources
WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
TOKYO and CHIPPENHAM, England, October 7 /PRNewswire-FirstCall/ --
Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura
Group plc ("Vectura"; LSE: VEC), announce results of two Phase II studies
evaluating the efficacy, safety and tolerability of NVA237 presented at the
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Data support the therapeutic potential of Amylin's integrated neurohormonal approach to obesity pharmacotherapy
SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN ) today announced that new data for its pipeline obesity
candidates will be pre...
ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
LEUVEN, Belgium, September 29 /PRNewswire-FirstCall/ --
- Results Presented at World Stroke Congress in Vienna
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company
focused on novel therapies for eye disease, vascular disease and cancer,
announces positive results from its MIT...
Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
SUNRISE, Fla., Sept. 18 /PRNewswire/ -- A preclinical study involving
the injection of adipose-derived stem cells (ADSCs) into the myocardium
(heart muscle tissue) of infarcted rats, was recently completed at the
Jordan University of Science and Technology in Irbid, Jordan by medical and
Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
Significant Research Presented at the AHCC International Research Symposium
PURCHASE, N.Y., Sept. 16 /PRNewswire/ -- The 16th International AHCC(R)
(Active Hexose Correlated Compound) Symposium was held in Sapporo, Japan on
July 26th and 27th. The Symposium hosted by the AHCC Research Associatio...
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Pre-Clinical Data Shows Increased Muscle and Blood Vessel Formation in Animals' Hearts
SUNRISE, Fla., July 24 /PRNewswire-FirstCall/ -- Results of a
preclinical study involving the injection of myoblasts modified to express
stromal derived factor-1(alpha) protein (S...
Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease
NEW YORK, July 17 /PRNewswire-USNewswire/ -- The Michael J. Fox
Foundation for Parkinson's Research today announced approximately $2.4
million in total funding to nine research teams under its Target Validation
initiative. This annual MJFF program provides intellectual and financial
HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
FDA Feedback Supports Innovative Co-development Model
SAN DIEGO, June 17 /PRNewswire/ -- Bio International Convention 2008
( http://www.bio2008.org ) -- HUYA Bioscience International
( http://www.huyabio.com ), the leader in U.S./China pharmaceutical
co-development, today announced th...
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera
Corporation (Nasdaq: GENR ) announced today a presentation by Genaera
scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead
drug candidate for the treatment of type 2 diabetes and obesity, during the
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
Tumor responses, safety and long-term survivors validate Jennerex breakthrough product approach
SAN FRANCISCO and YONGIN-SI, South Korea, May 21 /PRNewswire/ --
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South
Korean partner Green Cross Corp., announ...
Amikacin Inhale Shows Promising Results in Phase II Study
- Bayer together with Nektar Therapeutics present preliminary Phase II data for the adjunctive treatment of pneumonia in intubated and mechanically-ventilated patients
TORONTO and BERLIN, May 19 /PRNewswire-FirstCall/ -- Bayer HealthCare
together with Nektar Therapeutics...
HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
FDA feedback validates HUYA's Integrated Co-Development Model for China-sourced Drug Candidates
SAN DIEGO, April 14 /PRNewswire/ -- HUYA Bioscience International
(HUYA), the leader in U.S./China pharmaceutical co-development, today
announced the outcome of the first pre-...
HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
Progress validates HUYA's innovative U.S./China pharmaceutical co-development model
SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA
Bioscience International (HUYA), the leader in U.S./China pharmaceutical
co-development, today announced the completio...
Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
Four industry research projects targeted as part of innovative
Therapeutics Development Initiative
NEW YORK, Jan. 31 /PRNewswire-USNewswire/ -- As part of its ongoing
efforts to do whatever it takes to speed delivery of transformative
treatments and a cure for Parkinson's disease, The Mich...
Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
New data supports recent IND and forms foundation for upcoming clinical programs
PLYMOUTH MEETING, Pa., Jan. 24 /PRNewswire-FirstCall/ -- Genaera
Corporation (Nasdaq: GENR ) announced today a poster presentation of
preclinical data on trodusquemine (MSI-1436), G...
Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
CARMIEL, Israel, Jan. 22 /PRNewswire-FirstCall/ -- Protalix
BioTherapeutics, Inc. (Amex: PLX ), today announced that it has achieved
proof of concept results in an animal study conducted as part of its
Acetylcholinesterase (AChE) Program. The Acetylcholinesterase (AChE)
Program is being condu...
AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
TUCSON, Ariz., Jan. 3 /PRNewswire/ -- AmpliMed today reported one year
survival results from a Phase I/II trial of its lead drug candidate,
Amplimexon(R) (imexon for injection) in combination with dacarbazine in
patients with unresectable stage III or stage IV metastatic malignant
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Plans to Move Forward with Phase III
MALVERN, Pa., Oct. 17 /PRNewswire/ -- Cutanea Life Sciences, an
emerging specialty pharmaceutical company focused on improving human health
and appearance through the development and commercialization of treatments
for diseased and aging s...
NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
SOPHIA ANTIPOLIS, France, Oct. 2 /PRNewswire-FirstCall/ -- NicOx S.A.
(Eurolist: COX) today announced the presentation of promising
preclinical results from its collaboration with Ferrer Grupo International
at the 21st World Congress of Dermatology, in Buenos Aires, Argentina.
The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
WHITE PLAINS, N.Y., Sept. 18 /PRNewswire/ -- Millennium Pharmaceuticals
and Johnson & Johnson have reported that an interim analysis of a large,
randomized, international Phase III trial comparing melphalan-prednisone
(MP) with MP in combination with Velcade(R) (bortezomib) showed that the
NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
SOPHIA ANTIPOLIS, France, Sept. 11 /PRNewswire/ -- NicOx S.A.
(Eurolist: COX) today reported that TOPIGEN Pharmaceuticals Inc. has
top-line results from its first phase 2 clinical study
for TPI-1020, a new chemical entity licensed from NicOx which is a novel
Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
GRONINGEN, Netherlands, Aug. 31 /PRNewswire-FirstCall/ -- Oncology
focused pharmaceutical development company Kiadis Pharma announced today
that it has successfully completed a Phase II clinical trial evaluating its
product Reviroc(TM). Reviroc is used to eliminate cancer cells from an
ImmuneRegen BioSciences Announces Promising Data on Homspera
Suggesting Potential as a Co-Therapeutic Agent
Compound Could Be Utilized as an Adjuvant and Play Key Role in the
Treatment of Influenza and Cancer
SCOTTSDALE, Ariz., March 20, 2007 /PRNewswire-FirstCall/ --
ImmuneRegen BioSciences, a wholly owned subsidiary of IR
BioSciences Holdings, Inc. , announced today that data obtained by
the Company o...
Arpida Announces Promising Results of "First-In-Man" Studies With
High Concentrations Reached in Key Lung Compartments
REINACH and BASEL, Switzerland, March 29, 2007
/PRNewswire-FirstCall/ -- Arpida Ltd. today announced promising
results of "first-in-man" studies with AR-709. These radiolabelled
Human Microdose studies included a total of 19 healthy male
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the
Subject of Promising New Alzheimer's Research
In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation
ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene,
Inc., a leading biodefense company specializing in the development
and commercialization of medical countermeasures against chemical
and biological terrorism, announced today ...
Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the
Subject of Promising New Alzheimer's Research
In Vitro Assays Show rBChE Suppresses Amyloid Plaque
ANNAPOLIS, Md., April 3, 2007 - PharmAthene, Inc., a leading
biodefense company specializing in the development and
commercialization of medical countermeasures against chemical and
biological terrorism, announced today that new data...
Biomira Selects PX-866 as Clinical Development Candidate and
Presents Promising Preclinical Data at AACR
-IND filing expected by end of 2007-
EDMONTON, April 16, 2007 /PRNewswire-FirstCall/ - Biomira Inc.
today announced that it has selected PX-866 as its next clinical
development candidate. PX-866 is an inhibitor of the
phosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, an
Targeting Specific Mutations Reveals Promising New Approach to
Treating Genetic Disorders; Preclinical Data Published in Nature
PTC124 Targets Nonsense Mutations; Addresses Underlying Cause of
Genetic Disorders and Restores Protein Function
SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire/ -- New
preclinical data published online in the current edition of the
journal Nature show that PTC124, an investigational new drug
Insmed Announces Promising Results From IPLEX Phase II Myotonic
Muscular Dystrophy Clinical Study
RICHMOND, Va.--(BUSINESS WIRE)--May 3, 2007 - Insmed Inc.
(Nasdaq:INSM) today announced positive results from a Phase II
investigator-sponsored study of the company's drug, IPLEX(TM), in
patients with myotonic muscular dystrophy (DM1).
Preliminary results of the clinical study, being conducted at
Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro
Studies for Promising Alzheimer's Drug
Samaritan Announces Positive Data in Nonclinical (IND) In- Vitro
Studies for Promising
LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- Samaritan
Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,
is pleased to announce positive results were attained with its
IR BioSciences Announces Promising Data from Study of Its Compound
Data Suggests Homspera Shows Promise As an Adjuvant for Vaccines
against Avian Flu and Other Viruses
SCOTTSDALE, Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IR
BioSciences Holdings, Inc. announced today that preliminary data
from its influenza vaccine adjuvant study being performed in
XTENT Announces Promising Six-Month Custom II Trial Data Presented
at EuroPCR Meeting
Trial Included One of the Most Challenging Patient Populations
Studied of Any Drug-Eluting Stent (DES) Clinical Trial
BARCELONA and MENLO PARK, Calif., May 22, 2007
/PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-month
follow-up data from the CUSTOM II clinical trial, which assessed
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241
in Patients With Advanced Solid Tumors
SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc.
(NASDAQ:INGN) reported promising
Phase 1/2 clinical data with INGN
241, the Company's novel investigational mda-7/IL-24 tumor
suppressor agent, in patients with advanced solid tumors.
The data (Abstract #380), which were presented...
Poniard Pharmaceuticals Announces Promising Data From Interim
Safety Analysis of Phase 1 Combination Trials of Picoplatin in
Colorectal and Prostate Cancers
- Company Planning to Initiate Phase 2 Trials in Colorectal Cancer
and in Hormone-Refractory Prostate Cancer in Q307 -
SOUTH SAN FRANCISCO, Calif., June 01, 2007
/PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a
biopharmaceutical company focused on oncology, today announced